Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Saglik Bilimleri Universitesi

Status: Enrolling

Conditions: Age Related Macular Degeneration; Anti Vascular Endothelial Growth Factor; Exudative Age-Related Macular Degeneration

Treatments: Drug: Aflibercept biosimilar (MY-1701P)

Study type: Observational

Funder types: Other

Identifiers

NCT07235527

skalpakoglu

Details and patient eligibility

About

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Enrollment: 54 estimated patients

Sex: All

Ages: 45 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
• who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
• for whom intravitreal injection has already been clinically indicated

Exclusion criteria

• Patients younger than 45 years or older than 90 years
• History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
• Presence of uveitis
• Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
• Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
• Presence of hereditary retinal dystrophies
• Presence of optic atrophy

Trial design

54 participants in 1 patient group

patients treated with Yesafili

Description:

aflibercept biosimilar used

Treatment:

Drug: Aflibercept biosimilar (MY-1701P)